Vijoice® (alpelisib) – New formulation approval
April 24, 2024 - The FDA approved Novartis’ Vijoice (alpelisib) oral granules, for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.